Abstract
Tetrahydroisoquinolines have been widely investigated for the treatment of arrhythmias. 1−(3′−bromophenyl)−heliamine (BH), an anti−arrhythmias agent, is a synthetic tetrahydroisoquinoline. This study focuses on the pharmacokinetic characterization of BH, as well as the identification of its metabolites, both in vitro and in vivo. A UHPLC−MS/MS method was developed and validated to quantify BH in rat plasma with a linear range of 1–1000 ng/mL. The validated method was applied to a pharmacokinetic study in rats. The maximum concentration Cmax (568.65 ± 122.14 ng/mL) reached 1.00 ± 0.45 h after oral administration. The main metabolic pathways appeared to be phase-I of demethylation, dehydrogenation, and epoxidation, and phase II of glucuronide and sulfate metabolites. Finally, a total of 18 metabolites were characterized, including 10 phase I metabolites and 8 phase II metabolites. Through the above studies, we have gained a better understanding of the absorption and metabolism of BH in vitro and in vivo, which will provide us with guidance for future in-depth studies on this compound.
Funder
National Key R&D Program of China
Xinjiang Uygur Autonomous Region Regional Collaborative Innovation Special Project
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference31 articles.
1. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): A prospective cohort study;Dehghan;Lancet,2017
2. (2022). Report on cardiovascular health and diseases in China 2021: An updated summary. Chin. Health Econ., 37, 533–578.
3. Epigenetic regulation in cardiovascular disease: Mechanisms and advances in clinical trials;Shi;Signal Transduct. Target. Ther.,2022
4. Pharmacist interventions for medication adherence: Community guide economic reviews for cardiovascular disease;Jacob;Am. J. Prev. Med.,2022
5. The global burden of cardiovascular diseases and risks;Roth;J. Am. Coll. Cardiol.,2020